Evaluation of Cardiac Electrophysiological Examination for Anthracycline Related Early Cardiotoxicity in Children with Leukemia or Solid Tumor

XU Xin-yi,HUANG Mei-rong,TANG Jing-yan,XING Hai-hua,ZHANG Yu-qi,WU Yu-rong,ZHOU Min
DOI: https://doi.org/10.3969/j.issn.1003-515x.2011.13.008
2011-01-01
Abstract:Objective To evaluate the feasibility of cardiac electrophysiological examinations for detecting the anthracycline(ANT) related early cardiotoxicity in pediatric patients with leukemia or solid tumor.Methods Between Aug.2003 and Mar.2009,65 patients who received and finished received ANT therapy because of leukemia or solid tumor were enrolled in this study.Among the patients,38 cases were male and 27 cases were female.Their ages ranged 1-16(6±4) years,while the age at the beginning of the ANT therapy as 5-14(4.0±4.5) years.The intervals between completing their therapy and the follow-up study were 1-49(20.88±13.23) months.The cumulative dose of ANT estimated with the conversion factor assessed by the equivalent dose of doxorubicin were 25-350(125.82±74.85) mg·m-2.The QTc and traditional echocardiography(2-DE) of the patients were compared to 25 healthy children(healthy control group).The heart variability(HRV) of the patients was compared with normal value.Results All the patients had a normal cardiac function of left ventricle.There was no significant difference of 2-DE results between patients and controls.In the follow-up,the QTc intervals were prolonged in 44 cases,in 3 patients were prolonged beyond the normal value( 440 ms).The QTc interval of patients after chemotherapy was significantly longer than that before chemotherapy and controls.No relationship was found between the prolongation of QTc intervals and accumulative doses of ANT or the follow-up period.The HRV(time and frequency domains) of the patients were depressed significantly compared with those in control group,and in 17 cases the value was beyond the normal.There was a significant change in HRV among patients with longer follow-up duration or taking a high dose of vincristine after chemotherapy.Conclusions The patients had low risk to get adverse cardiac attack within 1-49(20.88±13.23) months follow-up period and 25-350(125.82±74.85) mg·m-2 ANT dose range;but they still need a long-term follow-up because the reduced cardiovascular repolarization and anthracycline caused HRV.Compared to traditional 2-DE level,QTc and HRV can be the sensitive parameters to detect ANT related early cardiotoxicity.ANT therapy with a large does of vincristine might be risk factor in ANT related cardiotoxicity.
What problem does this paper attempt to address?